Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection
- PMID: 12208763
Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection
Abstract
Interleukin (IL)-12 activates a T-cell-dependent antitumor immune response that is able to eradicate established large tumors in a number of immunogenic tumor models. The effector mechanisms in these dramatic antitumor responses have not yet been identified. In this report, we show that the effector mechanism of IL-12-induced rejection of established MCA207 tumors is unique in that it is not dependent on perforin, Fas/Fas ligand, and nitric oxide. Study of cyclophosphamide plus IL-12 (Cy + IL-12)-induced rejection of ascites Sa1 tumor demonstrates that macrophages are the predominant immune cell infiltration in the ascites. These macrophages possess nonspecific tumoricidal activity in vivo as immune distinct MCA207 tumor cells inoculated i.p., but not s.c., in mice bearing regressing Sa1 ascites tumors after Cy + IL-12 therapy are rejected. Furthermore, Cy + IL-12-treated Sa1 ascites cells or macrophages, but not spleen macrophages from the same mouse or inflammatory macrophages induced by thioglycollate, are able to suppress the development of immune-irrelevant s.c. tumors in a Winn assay. These macrophages kill various tumor cells in a contact-dependent manner in vitro, and the cytotoxicity is preserved after fixation with paraformaldehyde. These results demonstrate that activated macrophages function as effector cells in an IL-12-induced, T-cell-dependent eradication of established tumors through a novel contact-dependent, paraformaldehyde fixation-resistant, apoptosis-inducing mechanism.
Similar articles
-
Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.J Immunol. 1999 Jul 15;163(2):583-9. J Immunol. 1999. PMID: 10395644
-
Ca2+-dependent, Fas- and perforin-independent apoptotic death of allografted tumor cells by a type of activated macrophage.J Immunol. 1997 Jul 1;159(1):15-21. J Immunol. 1997. PMID: 9200433
-
Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12.J Immunol. 1998 Feb 1;160(3):1369-77. J Immunol. 1998. PMID: 9570556
-
Potential for specific cancer therapy with immune T lymphocytes.J Biol Response Mod. 1984;3(2):113-27. J Biol Response Mod. 1984. PMID: 6233396 Review.
-
Role of macrophages in the expression of immune responses.J Am Vet Med Assoc. 1982 Nov 15;181(10):1037-42. J Am Vet Med Assoc. 1982. PMID: 6757210 Review.
Cited by
-
The Macrophage Activator GcMAF-RF Enhances the Antitumor Effect of Karanahan Technology through Induction of M2-M1 Macrophage Reprogramming.J Immunol Res. 2024 Feb 29;2024:7484490. doi: 10.1155/2024/7484490. eCollection 2024. J Immunol Res. 2024. PMID: 38455363 Free PMC article.
-
Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade.J Immunother Cancer. 2023 Nov;11(11):e007661. doi: 10.1136/jitc-2023-007661. J Immunother Cancer. 2023. PMID: 37918918 Free PMC article.
-
Theoretical premises of a "three in one" therapeutic approach to treat immunogenic and nonimmunogenic cancers: a narrative review.Transl Cancer Res. 2021 Nov;10(11):4958-4972. doi: 10.21037/tcr-21-919. Transl Cancer Res. 2021. PMID: 35116346 Free PMC article. Review.
-
Interleukin-12 as an in situ cancer vaccine component: a review.Cancer Immunol Immunother. 2022 Sep;71(9):2057-2065. doi: 10.1007/s00262-022-03144-1. Epub 2022 Jan 13. Cancer Immunol Immunother. 2022. PMID: 35024897 Free PMC article. Review.
-
Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages.Cells. 2021 Sep 9;10(9):2364. doi: 10.3390/cells10092364. Cells. 2021. PMID: 34572013 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous